NSCLC_treatment_sequencing_survey

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC  More than one-third of physicians report not having sufficient information to decide on how to sequence specific targeted lung cancer treatmentsSurvey findings presented today as a late-breaking abstract at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news